Fresenius Medical Care Corp (FMS) 44.07 $FMS St
Post# of 273249
Posted On: 09/27/2016 3:12:03 PM
Fresenius Medical Care Corp (FMS) 44.07 $FMS
Statement of Fresenius Medical Care North America Regarding Centers for Medicare & Medicaid Services Request for Information
BusinessWire - Fri Aug 19, 6:07PM CDT
In response to the Centers for Medicare & Medicaid Services' (CMS) recent Request for Information, Fresenius Medical Care North America issued the following statement:
FMS: 44.07 (-0.09)
Fresenius Medical (FMS) Q2 Earnings & Sales Lag Estimates
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:56AM CDT
Fresenius Medical Care (FMS) reported adjusted earnings of 48 cents per American Depositary Share (ADS) in the second quarter of 2016, missing the Zacks Consensus Estimate by a penny.
BABY: 39.27 (-0.44), MASI: 59.67 (+0.51), CPHD: 52.65 (+0.02), FMS: 44.07 (-0.09)
Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 313.92 (+4.10), INVA: 11.28 (+0.15), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09)
Fresenius Renal Therapies Announces the Introduction of Next Generation Sentinel Technology to Support Fluid Management Challenges in the End Stage Renal Disease Community
BusinessWire - Mon May 02, 8:51AM CDT
Fresenius Renal Therapies, a division of Fresenius Medical Care North America (FMCNA), the leading provider of products and services for the chronic kidney disease patient, announced today the introduction of its latest technological enhancement in the Crit-Line(R) technology product line, the CLiC(TM) device.
FMS: 44.07 (-0.09)
Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 8:14AM CDT
Amgen's (AMGN) growth products have started delivering, accounting for more than half of Q1 revenues.
MDVN: 81.47 (+0.05), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09), CELG: 107.30 (+0.99)
Fresenius Medical Care North America to Present Range of Clinical Findings Focused on Improving Renal Patient Care and Health Outcomes at the National Kidney Foundation 2016 Spring Clinical Meetings
BusinessWire - Mon Apr 25, 8:44AM CDT
Fresenius Medical Care North America (FMCNA), the continent's leading provider of kidney care products and services, announced today that the National Kidney Foundation (NKF) accepted a significant number of abstracts authored by FMCNA clinicians and caregivers for presentation at the 2016 Spring Clinical Meetings and publication in the journals affiliated with NKF. The general meeting is scheduled from April 28th to May 1st in Boston and is expected to attract more than 3,000 leading kidney professionals.
FMS: 44.07 (-0.09)
Amgen (AMGN) May Beat Q1 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Mon Apr 25, 7:30AM CDT
Cost control efforts, share buybacks and better-than-expected performance of new and mature products could help Amgen (AMGN) beat earnings expectations for Q1.
BMRN: 96.45 (+0.58), GILD: 79.10 (-1.52), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09)
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
Marketwired - Tue Feb 09, 6:31AM CST
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (FRANKFURT : FME)(NYSE: FMS), the worlds' largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo(TM) technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
FMS: 44.07 (-0.09)
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook
Arpita Dutt - Zacks Investment Research - Fri Jan 29, 8:05AM CST
Amgen's (AMGN) fourth quarter results were better-than-expected with products like Enbrel, Kyprolis, Sensipar, Prolia, and Xgeva driving growth.
GILD: 79.10 (-1.52), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09), CELG: 107.30 (+0.99)
MedAssets' Shareholders Approve Takeover by Pamplona
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 1:50PM CST
MedAssets (MDAS) recently announced the approval of the previously considered merger agreement with Pamplona Capital Management, a specialist investment manager, by its shareholders.
EXAC: 27.52 (+0.18), FMS: 44.07 (-0.09), MDAS: 31.35 (+0.01), ARAY: 5.81 (+0.28)
Statement of Fresenius Medical Care North America Regarding Centers for Medicare & Medicaid Services Request for Information
BusinessWire - Fri Aug 19, 6:07PM CDT
In response to the Centers for Medicare & Medicaid Services' (CMS) recent Request for Information, Fresenius Medical Care North America issued the following statement:
FMS: 44.07 (-0.09)
Fresenius Medical (FMS) Q2 Earnings & Sales Lag Estimates
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:56AM CDT
Fresenius Medical Care (FMS) reported adjusted earnings of 48 cents per American Depositary Share (ADS) in the second quarter of 2016, missing the Zacks Consensus Estimate by a penny.
BABY: 39.27 (-0.44), MASI: 59.67 (+0.51), CPHD: 52.65 (+0.02), FMS: 44.07 (-0.09)
Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 313.92 (+4.10), INVA: 11.28 (+0.15), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09)
Fresenius Renal Therapies Announces the Introduction of Next Generation Sentinel Technology to Support Fluid Management Challenges in the End Stage Renal Disease Community
BusinessWire - Mon May 02, 8:51AM CDT
Fresenius Renal Therapies, a division of Fresenius Medical Care North America (FMCNA), the leading provider of products and services for the chronic kidney disease patient, announced today the introduction of its latest technological enhancement in the Crit-Line(R) technology product line, the CLiC(TM) device.
FMS: 44.07 (-0.09)
Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 8:14AM CDT
Amgen's (AMGN) growth products have started delivering, accounting for more than half of Q1 revenues.
MDVN: 81.47 (+0.05), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09), CELG: 107.30 (+0.99)
Fresenius Medical Care North America to Present Range of Clinical Findings Focused on Improving Renal Patient Care and Health Outcomes at the National Kidney Foundation 2016 Spring Clinical Meetings
BusinessWire - Mon Apr 25, 8:44AM CDT
Fresenius Medical Care North America (FMCNA), the continent's leading provider of kidney care products and services, announced today that the National Kidney Foundation (NKF) accepted a significant number of abstracts authored by FMCNA clinicians and caregivers for presentation at the 2016 Spring Clinical Meetings and publication in the journals affiliated with NKF. The general meeting is scheduled from April 28th to May 1st in Boston and is expected to attract more than 3,000 leading kidney professionals.
FMS: 44.07 (-0.09)
Amgen (AMGN) May Beat Q1 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Mon Apr 25, 7:30AM CDT
Cost control efforts, share buybacks and better-than-expected performance of new and mature products could help Amgen (AMGN) beat earnings expectations for Q1.
BMRN: 96.45 (+0.58), GILD: 79.10 (-1.52), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09)
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
Marketwired - Tue Feb 09, 6:31AM CST
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (FRANKFURT : FME)(NYSE: FMS), the worlds' largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo(TM) technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
FMS: 44.07 (-0.09)
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook
Arpita Dutt - Zacks Investment Research - Fri Jan 29, 8:05AM CST
Amgen's (AMGN) fourth quarter results were better-than-expected with products like Enbrel, Kyprolis, Sensipar, Prolia, and Xgeva driving growth.
GILD: 79.10 (-1.52), AMGN: 171.11 (-2.42), FMS: 44.07 (-0.09), CELG: 107.30 (+0.99)
MedAssets' Shareholders Approve Takeover by Pamplona
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 1:50PM CST
MedAssets (MDAS) recently announced the approval of the previously considered merger agreement with Pamplona Capital Management, a specialist investment manager, by its shareholders.
EXAC: 27.52 (+0.18), FMS: 44.07 (-0.09), MDAS: 31.35 (+0.01), ARAY: 5.81 (+0.28)
(0)
(0)Scroll down for more posts ▼